Introduction: Hyperuricemia has been associated with the development of hypertension,
cardiovascular, and renal disease.
Objectives: We conducted a prospective study to investigate the benefits of allopurinol
treatment in hyperuricemic patients with chronic kidney disease (CKD) stage 3.
Patients and Methods: Our study includes a total of 132 patients (41 females and 91 males)
with CKD grade 3 who are followed up by the pre-dialysis polyclinic. Around 67 of these
patients administered allopurinol while 65 patients were not administered. The therapy
protocol for the patients was allopurinol 150 mg/d and the duration of the follow-up was 12
months. Clinical records of the patients were screened, to start with 3, 6, 9 and 12 months,
eGFR (estimated glomerular filtration rate) values were calculated.
Results: The patients’ eGFR with allopurinol treatment was increased compared with baseline
values. 12th month increased by 1.02 ± 8.89 mL/min/1.73 m2 from baseline in eGFR, but it was
not statistically significant (P = 0.352). In the control group 12th month showed a decrease in
baseline GFR value of 2.59 ± 7.9 mL/min/1.73 m2 (P = 0.012). The 3, 6, 9, 12th months compared
with baseline in the allopurinol treatment group showed a significant decrease in uric acid
value (P < 0.05).
Conclusion: Decreased renal progression was observed by reduction of serum uric acid levels
at stage 3 hyperuricemic CKD with allopurinol. The annual decline in GFR in hyperuricemic
patients, is more than normouricemic patients.